Jie Dong1, Qin Wang1, Meng-Hua Chen1, Hui-Ping Zhao1, Tong-Ying Zhu1, Na Tian1, Mei Wang1, Chuan-Ming Hao1, Ye-Ping Ren1, Hai-Yan Wang1. 1. Renal Division, Department of Medicine, Peking University First Hospital; Institute of Nephrology, Peking University; Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China; Department of Nephrology, Second Affiliated Hospital of Harbin Medical University, Heilongjiang, China; Department of Nephrology, General Hospital of Ningxia Medical University, Ningxia, China; Department of Nephrology, Peking University People's Hospital, Beijing, China; and Department of Nephrology, Huashan Hospital of Fudan University, Shanghai, China.
Abstract
INTRODUCTION: Although previous studies have suggested associations between serum intact parathyroid hormone (iPTH), 25-hydroxyvitamin D (25(OH)D) and metabolic syndrome (MS) in the general population, these associations are still uncharacterized in peritoneal dialysis (PD) patients. METHODS: In total, 837 prevalent PD patients from 5 centers in China were enrolled between April 1, 2011 and November 1, 2011. The demographic data, biochemical parameters and medical records were collected, except for serum 25(OH)D which was measured in 347 of 837 patients. The definition of MS was modified from National Cholesterol Education Program Third Adult Treatment Panel (NCEP-ATPIII). RESULTS: 55.4% of 837 patients were found to have MS. The median concentration of iPTH, 25(OH)D and doses of oral vitamin D analogs for participants with MS was significantly lower than those without MS. The iPTH, 25(OH)D values and doses of vitamin D analogs were all associated with one or more components of MS. After multivariate adjustment, low serum iPTH values and oral vitamin D analogs, rather than serum 25(OH)D, were significantly associated with the presence of MS, abnormal fasting blood glucose (FBG) and high-density lipoprotein cholesterol (HDL-C). Compared to iPTH < 130 pg/mL, iPTH 130-585 pg/mL and > 585 pg/mL were associated with a lower risk of MS with adjusted odds ratio (OR) of 0.59 and 0.33, respectively. Taking vitamin D analogs was also associated with a lower risk of MS with adjusted OR of 0.55. CONCLUSIONS: Serum iPTH and the use of active vitamin D supplements rather than serum 25(OH)D were independently associated with the presence of MS in patients on PD.
INTRODUCTION: Although previous studies have suggested associations between serum intact parathyroid hormone (iPTH), 25-hydroxyvitamin D (25(OH)D) and metabolic syndrome (MS) in the general population, these associations are still uncharacterized in peritoneal dialysis (PD) patients. METHODS: In total, 837 prevalent PDpatients from 5 centers in China were enrolled between April 1, 2011 and November 1, 2011. The demographic data, biochemical parameters and medical records were collected, except for serum 25(OH)D which was measured in 347 of 837 patients. The definition of MS was modified from National Cholesterol Education Program Third Adult Treatment Panel (NCEP-ATPIII). RESULTS: 55.4% of 837 patients were found to have MS. The median concentration of iPTH, 25(OH)D and doses of oral vitamin D analogs for participants with MS was significantly lower than those without MS. The iPTH, 25(OH)D values and doses of vitamin D analogs were all associated with one or more components of MS. After multivariate adjustment, low serum iPTH values and oral vitamin D analogs, rather than serum 25(OH)D, were significantly associated with the presence of MS, abnormal fasting blood glucose (FBG) and high-density lipoprotein cholesterol (HDL-C). Compared to iPTH < 130 pg/mL, iPTH 130-585 pg/mL and > 585 pg/mL were associated with a lower risk of MS with adjusted odds ratio (OR) of 0.59 and 0.33, respectively. Taking vitamin D analogs was also associated with a lower risk of MS with adjusted OR of 0.55. CONCLUSIONS: Serum iPTH and the use of active vitamin D supplements rather than serum 25(OH)D were independently associated with the presence of MS in patients on PD.
Authors: James L Vacek; Subba Reddy Vanga; Mathew Good; Sue Min Lai; Dhanunjaya Lakkireddy; Patricia A Howard Journal: Am J Cardiol Date: 2011-11-08 Impact factor: 2.778
Authors: Jared P Reis; Denise von Mühlen; Donna Kritz-Silverstein; Deborah L Wingard; Elizabeth Barrett-Connor Journal: Diabetes Care Date: 2007-03-10 Impact factor: 19.112
Authors: Raymond R Townsend; Amanda H Anderson; Jing Chen; Crystal A Gadebegku; Harold I Feldman; Jeffrey C Fink; Alan S Go; Marshall Joffe; Lisa A Nessel; Akinlolu Ojo; Daniel J Rader; Muredach P Reilly; Valerie Teal; Karen Teff; Jackson T Wright; Dawei Xie Journal: Am J Nephrol Date: 2011-04-27 Impact factor: 3.754
Authors: John K Ninomiya; Gilbert L'Italien; Michael H Criqui; Joanna L Whyte; Anthony Gamst; Roland S Chen Journal: Circulation Date: 2003-12-15 Impact factor: 29.690
Authors: David E Laaksonen; Hanna-Maaria Lakka; Leo K Niskanen; George A Kaplan; Jukka T Salonen; Timo A Lakka Journal: Am J Epidemiol Date: 2002-12-01 Impact factor: 4.897